Effectiveness of a nurse practitioner-led cardiovascular prevention clinic at reduction of metabolic syndrome following maternal complications of pregnancy: a preliminary analysis

Table 3 Mean change in cardiometabolic risk factors over time

	No MetS at either time point, n = 37	MetS at first timepoint, no MetS at second timepoint (MetS resolved), n = 8	No MetS at either timepoint, n = 14	Developed MetS during study: No MetS at first timepoint, MetS at second timepoint, n = 5
BMI, kg/m²	0.31 ± 2.40	− 0.87 ± 2.63	0.29 ± 1.49	0.08 ± 1.42
Waist circumference, cm	− 0.21 ± 12.88	− 3.71 ± 4.22	0.39 ± 5.52	− 0.02 ± 2.94
Peripheral SBP, mmHg	− 4.57 ± 19.90	− 3.12 ± 8.22	− 1.64 ± 11.00	3.20 ± 6.65
Peripheral DBP, mmHg	− 2.54 ± 14.67	− 1.38 ± 9.97	1.21 ± 8.67	3.20 ± 9.26
Triglycerides, mmol/L	− 0.09 ± 0.78	− 0.45 ± 0.67	0.12 ± 0.77	0.32 ± 0.25
HDL cholesterol, mmol/L	0.54 ± 0.41	0.10 ± 0.19	− 0.50 ± 0.13	0.40 ± 0.27
Glucose, mmol/L	0.22 ± 1.97	− 0.20 ± 1.21	0.41 ± 1.80	0.44 ± 0.89
Insulin, mU/L	− 1.44 ± 16.16	− 12.58 ± 16.44	1.10 ± 10.69	− 0.42 ± 8.26
HOMA-IR	− 0.39 ± 3.66	− 3.26 ± 5.02	0.34 ± 3.56	0.15 ± 2.32

Data are presented as mean ± standard deviation. ‘Improve’ denotes those who had MetS at the first time point but did not meet the criteria at the second time point. ‘No change’ denotes those who had MetS at both time points. ‘Worse’ denotes those who did not have MetS at the first time point but met the criteria at the second timepoint
MetS metabolic syndrome, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, HDL high-density lipoprotein, HOMA-IR Homeostatic Model Assessment for Insulin Resistance

ISSN: 1758-5996